Congratulations @MeghnaTrivedi3@RueterJens@Amich1122@DrDawnHershman et al for their Featured Abstract @ #ASCOQLTY23: "Mixed-methods analysis of physician genomic confidence in ... cluster randomized trial evaluating genomic tumor boards (@SWOG S2108CD)" https://t.co/m4IqQvKyLR
🚨🚨Exciting news! Hot off the press with a simultaneous publication in @AACR Cancer Discovery @CD_AACR with the @ASCO#ASCO23 clinical science symposium meeting 👉🏼 So honored to present to the world 👉🏼RLY-4008 - the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations & resistance mutations.
🔺Promising results in FGFR2-positive cholangiocarcinoma & other advanced solid tumors @OncoAlert@ElizSMcKenna@AliSchram@OncBrothers #PrecisionMedicine for the win 🎯🧬
https://t.co/pkyxqsMoCz
Universal germline testing in all cancer patients would certainly change current practice. While thought-provoking and intriguing, this will also require novel approaches in care delivery, including education of clinicians and patients. @jax_mcgi @JAXClinicalEd@JAXcancercenter
When not at @ASCO 2023…not so bad reading about the presentations in front of a nice wood stove fire on this uncharacteristically cool June day in Maine…
Dr. @NaglaAKarimMD presents results of @SWOG S1929 at #ASCO23:
Adding a PARP inhibitor (talazoparib) to checkpoint blockade significantly extended PFS for patients w extensive-stage small-cell #lungcancer whose tumors express SLFN11. Biomarker selected treatment in #SCLC#LCSM
.@KariWisinski_MD et al report on results from #NCI-MATCH trial where trametinib didn't meet its objective response rate goal in NF1, GNAQ or GNA11 altered tumors but some stable diseases observed suggest need to explore further in certain disease types: https://t.co/4PVsgT7icc
On the heels of this publication, it’s great to be at the Spring 2023 @SWOG meeting and run into @ARosen380 and listen to @MeghnaTrivedi3’s great talk at the Translational Medicine Plenary, mentioning our S2108CD cluster-randomized trial investigating genomic tumor boards
Biomedical researchers and clinical experts are giving guest lectures about cancer biology, the unique features of cancer genomes, bioinformatic approaches used in #CancerResearch and more.
Yesterday, Dr. Jens Rueter (@RueterJens) discussed human subjects research and @JAX_MCGI!
94% of individuals affected by cancer want to know genetic results which are preventable or treatable. 60% want to know, even if there are no treatments. @OmicoAustralia@UNSWMedicine#RisC study. https://t.co/kAvhahdOoo